Ohcanbohtosat - S.R. Schwid

  • Čájehuvvo 1 - 5 / 5
Aiddostahte ozu
  1. 1
    Cost-effectiveness of disease-modifying therapy for multiple sclerosis

    Cost-effectiveness of disease-modifying therapy for multiple sclerosis Dahkki Katia Noyes, Alina Bajorska, A T Chappel, S. R. Schwid, Lahar Mehta, Bianca Weinstock‐Guttman, Robert G. Holloway, Andrew W. Dick

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis

    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis Dahkki Steven R. Schwid, John Thorpe, Mohammad K. Sharief, Magnhild Sandberg‐Wollheim, Kottil Rammohan, Jeanette Wendt, Hillel S. Panitch, Douglas S. Goodin, David Li, Peter Chang, Gordon Francis

    Almmustuhtton 2005
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis Dahkki Lauren Krupp, Christopher Christodoulou, Patricia Melville, W. F. Scherl, L.-Y. Pai, L.R. Muenz, Dian He, R.H.B. Benedict, Andrew Goodman, Syed Rizvi, S.R. Schwid, Bianca Weinstock‐Guttman, Holly James Westervelt, H. Wishart

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease

    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease Dahkki Michael A. Schwarzschild, Steven R. Schwid, Kenneth Marek, Arthur Watts, Anthony E. Lang, David Oakes, Ira Shoulson, Alberto Ascherio, Christopher Hyson, Emily Gorbold, Alice Rudolph, Karl Kieburtz, Stanley Fahn, Lisa Gauger, Christopher G. Goetz, John Seibyl, M. Forrest, John Ondrasik

    Almmustuhtton 2008
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials Dahkki Andrew Goodman, François Béthoux, Theodore R. Brown, Randall T. Schapiro, Ron Cohen, Lawrence N. Marinucci, Herbert R. Henney, Andrew R. Blight, Mark Agius, B. G. W. Arnason, F. Béthoux, C. T. Bever, JD Bowen, TR Brown, D. Dietrich, Kelly Edwards, MS Freedman, Mark S. Freedman, NJ Kachuck, MD Kaufman, Marshall J. Keilson, Omar Khan, Lauren Krupp, TP Leist, John Lindsey, F.D. Lublin, MK Mass, D. E. Mattson, Denise McGowan, Robert T. Naismith, Colleen O’Connell, JJ Oger, Hillel S. Panitch, MA Picone, K Rammohan, RT Schapiro, S.R. Schwid, Thomas F. Scott, C Short, BW Thrower, TL Vollmer, Ann Camac, JA Cooper, WF Chumley, Anne H. Cross, RT Dunnigan, JS Gitt, Marij A. Hillen, DR Jeffrey, B. Khatri, Kiren Kresa-Reahl, Seok Whan Moon, Jana Lízrová Preiningerová, Mark Tullman, Bianca Weinstock‐Guttman, DR Wynn

    Almmustuhtton 2015
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: